Catalyst Wire Dossier Catalyst Wire Dossier

Linagliptin (Tradjenta)

linagliptin · Boehringer Ingelheim and Eli Lilly and Company
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Linagliptin (Tradjenta), covering 2013-03-26 to 2025-06-26. Get the full timeline:

Most recent: Clinical Trial Update: To Compare and Evaluate the Oral Bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg Filmcoated Tablets With That of Glyxambi 10 mg/ 5 mg Film-coated Tablets in Healthy, Adult, Human Subjects Under Fasting Conditions. [Phase 1]

See pricing